With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.

Sanofi Invests €40 Million to Boost Antibody Production in France

By Feliza Mirasol

November 21st 2024

The investment will allow Sanofi to strengthen antibody bioproduction at its Lyon Gerland site in France.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

SEKISUI Completes CDMO Capacity Expansion for CGMP Biopharma Manufacturing

By Feliza Mirasol

November 19th 2024

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

Avantor Geared for Biopharma Industry’s Future with Next-Generation Biotherapeutics

By Feliza Mirasol

November 14th 2024

Avantor executives discuss the future of the biopharmaceutical industry and the impact that a wave of next-generation biotherapeutics will bring.

Collaboration between Merck and Ginkgo Bioworks for Improving Biologics Manufacturing Achieves First Milestone

By Feliza Mirasol

November 12th 2024

Ginkgo Bioworks has achieved the first milestone in an ongoing partnership with Merck, known as MSD outside of the United States and Canada, aimed at improving biologics production.

...

23 24 25 26 27

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777